logo
NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

Yahoo25-06-2025
Ionophores, Commonly Used in Animal Agriculture, Found to Contribute to Antibiotic Resistance in Humans
Salisbury, MD, June 25, 2025 (GLOBE NEWSWIRE) -- A new study, published in mSphere, a journal of the American Society for Microbiology, suggests some antibiotics used in conventional poultry farming may contribute to the development of antibiotic resistance in humans. This research, conducted by Dr. Alex Wong, Asalia Ibrahim and Jason Au of Carleton University's Department of Biology, focuses on ionophores, a class of antibiotics commonly used in conventional poultry farming and previously described as 'not important to human medicine.'
'This research underscores the importance of understanding the interconnectedness of animal and human health,' explains Dr. Alex Wong. 'While ionophores have long been considered safe for use in poultry to prevent parasitic infections, this study suggests that ionophore use could fuel the growth of antibiotic resistance to medically relevant drugs.'
This study highlights the ongoing research and critical discussion about responsible antibiotic use in animal agriculture, showcasing the potentially negative long-term human and animal health effects of using antibiotics in animal production, even those not presently deemed 'important to human medicine."
The study found:
Bacterial pathogens around the world have genes (narA and narB) that allow them to resist ionophores.
These genes are often found linked to other resistance genes that protect bacteria from human antibiotics.
When ionophores are used, they can unintentionally encourage bacteria to carry both types of resistance – making them harder to kill with medicines we need and increasing the risk of clinically significant antimicrobial resistance spreading from animal agriculture to human healthcare systems.
The study's findings contribute to the ongoing scientific conversation about antibiotic resistance and inform future research and policy decisions and provides evidence that the widespread use of ionophores potentially threaten human health.
'This study surprised me. Personally, I've been dismissing the use of ionophores for years because we didn't have this evidence. This study suggests that it could be driving resistance to the drugs we do care about. When animal producers use ionophores they can drive the growth of bacteria that are resistant to our most important medicines,' Lance Price, M.S. Ph.D., Professor at George Washington's (GW) Milken Institute School of Public Health and Founding Director of GW's Antibiotic Resistance Action Center.
Perdue Takes No Chances with Animal or Human Health, Standing Firm on Its Decade-Long 'No Antibiotics Ever' Commitment
Ionophore use in poultry has been on the rise after a reintroduction of usage by large producers—with some poultry companies relying on routine use of the drug class for preventing illness. However, Perdue Farms took a trailblazing approach by committing to No Antibiotics Ever (NAE) in 2016, shunning the use of all antibiotics including ionophores.
Perdue Farms remains committed to its No Antibiotics Ever (NAE) program. 'We started our NAE transition initially due to consumer demand, however with time we have seen, and appreciate, the animal welfare and human health benefits of this approach,' states Dr. Bruce Stewart-Brown, DVM, Chief Science Officer at Perdue Farms. 'For a decade now, our No Antibiotics Ever commitment has reflected our belief that what's good for the bird is also good for people– and this study confirms that belief is well-founded. At the end of the day, it's a promise that gives consumers peace of mind and sets a higher standard for responsible poultry production.'
This research was funded by the Canadian Government, Natural Sciences and Engineering Research Council of Canada (NSERC) and Perdue Farms. Learn more about the study and Perdue Farms' commitment to NAE at corporate.perduefarms.com.
For media interested, there will be a virtual briefing today, June 25, at 10 AM ET. You can join that briefing using this link starting at 10 AM ET, or reach out to kerri.mcclimen@perdue.com for more detail.
###
About Perdue FarmsWe're a fourth-generation, family-owned, U.S. food and agriculture company. Through our belief in responsible food and agriculture, we are empowering consumers, customers, and farmers through trusted choices in products and services. Perdue Foods consists of a premium protein portfolio, including our flagship PERDUE® brand, Niman Ranch®, Coleman Natural®, Pasturebird®, and Yummy®, as well as our pet brands, Full Moon® and Spot Farms®, and is available through various channels including retail, foodservice, club stores and our direct-to-consumer website, PerdueFarms.com. Perdue AgriBusiness is a leading merchandiser, processor, and exporter of agricultural products and the largest U.S. manufacturer of specialty, organic, and non-GMO oils. It also ranks as one of the largest suppliers of organic feed ingredients in the world. Now in our company's second century, we never use drugs for growth promotion in raising poultry and livestock, and we are actively advancing our animal welfare programs. Our brands are leaders in no-antibiotics-ever and in USDA-certified organic proteins. Learn more at Corporate.PerdueFarms.com.
Attachment
Ionophores Report Infographic
CONTACT: Kerri McClimen Perdue Farms kerri.mcclimen@perdue.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Yahoo

time28 minutes ago

  • Yahoo

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact or visit 1AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer Media Contact Owen Blaschak LifeSci Communications oblaschak@

Federal investigators demanded details on transgender patients from at least 1 hospital
Federal investigators demanded details on transgender patients from at least 1 hospital

Yahoo

time28 minutes ago

  • Yahoo

Federal investigators demanded details on transgender patients from at least 1 hospital

When the U.S. Justice Department sought information from doctors and clinics that provide gender-affirming care for young transgender patients, officials weren't just asking for policies. They also demanded information about individual patients. Attorney General Pam Bondi announced in a statement July 9 that the department had sent more than 20 subpoenas to doctors and clinics that provide the care. The request represented an elevation in President Donald Trump's administration's effort to halt the medical treatment for transgender youth, even in states where it's legal. Bondi said the requests were part of investigations into 'healthcare fraud, false statements, and more.' No charges have been announced so far, but the probes have had a chilling impact on the availability of care. Specifics of the requests were not made public until a court filing in a separate lawsuit this week. Advocates say the requests are invasive and unnecessary. 'It turns doctor-patient confidentiality into government surveillance,' said Jennifer Levi, GLAD Law's senior director of Transgender and Queer Rights. At least one of the requests seeks names and social security numbers of patients The subpoena sent to Children's Hospital of Philadelphia on June 11 was included in a legal filing Monday in challenges from the states of Minnesota, Oregon and Washington to the administration's attempts to bar the treatment for patients under age 19. The 18-page document demanded an expansive list of documents be provided. Among them: Documents to identify 'by name, date of birth, social security number, address and parent/guardian information' patients who were prescribed puberty blockers or hormone therapy. The requests also covered personnel files for various categories of hospital employees, information about patient intake procedures and about which insurance billing codes the hospital used for gender-affirming care. The due date listed was July 9. It's not clear whether subpoenas sent to other providers were identical. Neither the hospital nor the Department of Justices responded to requests for comment on Thursday. Gender-affirming care has emerged as part of a political and legal battle Gender-affirming care includes a range of medical and mental health services to support a person's gender identity, including when it's different from the sex they were assigned at birth. It encompasses counseling, medications that block puberty and hormone therapy to produce physical changes as well as surgeries to transform chests and genitals, though those are rare for minors. Most major medical groups say access to the treatment is important for those with gender dysphoria and see gender as existing along a spectrum. While there's wide, if not universal, medical consensus, the political situation is contentious. Since 2021, at least 27 states have adopted laws restricting or banning the care for minors, and a U.S. Supreme Court ruling in June affirmed the states' right to have such policies, at least under certain conditions. Trump has signed one executive order defining sex as only male or female — and as unchangeable — and another that seeks to end federal funding of the care for patients under 19. He's also sought to bar transgender military service members and keep transgender athletes out of certain sports competitions. And the administration released a document that questions the standards of treatment for transgender youth and suggests relying solely on talk therapy rather than medical interventions. The investigation is one reason some clinics have halted the care At least eight major hospitals and hospital systems announced in July that they were stopping or restricting gender-affirming care, even though they're in states where it is not banned. Children's Hospital of Philadelphia is not among those that have announced they're curtailing care, though a place it has referred patients for surgeries — Penn Medicine — said in May that it would no longer perform them on patients under 19. A group of Democratic state officials across the country are suing the Trump administration, claiming it is intimidating healthcare providers to stop the care. GLAD Law's Levi said the investigation is just one of many factors that have led providers to change their policies. 'It's chilling,' she said. Solve the daily Crossword

Brookfield Zoo welcoming new polar bear this fall
Brookfield Zoo welcoming new polar bear this fall

CBS News

time31 minutes ago

  • CBS News

Brookfield Zoo welcoming new polar bear this fall

A new polar bear is coming to Chicago's Brookfield Zoo. The zoo is welcoming 8-year-old Amelia Gray, coming from Oregon. She will join the polar bears Hope and Hudson later this fall. "We look forward to welcoming Amelia Gray to Brookfield Zoo Chicago, as her arrival is a powerful opportunity to educate the community of the critical need to protect this vulnerable species," said Mark Wanner, associate vice president of animal care and conservation at Brookfield Zoo Chicago. Zoo officials said polar bears were the first species to be listed as threatened under the Endangered Species Act. They said this was primarily due to climate change.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store